Lactose
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Lactose
- Pharmacist Assessment Report
- Lactose: From Lactose Intolerance to Esophageal Varices with Bleeding
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Lactose: From Lactose Intolerance to Esophageal Varices with Bleeding
One-Sentence Summary
Lactose is a disaccharide sugar, originally used in products for managing lactose intolerance. The TxGNN model predicts it may be effective for esophageal varices with bleeding, but there are currently 0 clinical trials and 0 publications supporting this direction. This is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Lactose intolerance |
| Predicted New Indication | Esophageal varices with bleeding |
| TxGNN Prediction Score | 0.9993 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (2 of 2 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, lactose is a dietary disaccharide and a common pharmaceutical excipient. No mechanistic link to esophageal varices with bleeding has been identified.
The high prediction score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. One possible source of confusion is lactulose, a different compound used in hepatic encephalopathy (a complication of liver disease), which the model may conflate with lactose. The same score of 0.9993 for esophageal varices without bleeding supports the view that these predictions reflect learned similarities between related diseases.
Other top-ranked predictions (varicose disease, Steel syndrome, cystinosis, hypophosphatasia and others) likewise have no identified mechanism and no supporting trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 8587Y | Kindergen | Oral powder 400 g | Not available |
| ARTG 2870C | Renastart | Oral powder 400 g, 6 | Not available |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials, no literature and no plausible mechanism. It is most likely a TxGNN model (deep learning) artefact, so it does not currently justify further investment.
To proceed, the following is needed:
- Mechanism of action data for lactose and a credible biological rationale for esophageal varices
- Confirmation that the prediction is not driven by confusion with lactulose or other related compounds
- Any preclinical or clinical evidence supporting the proposed indication
- Approved indication text and safety information from the Product Information for the registered products
- Assessment of route compatibility and a safety screen before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.